13 11 20

Information and support

  • Get informed
  • Get support
  • Cut my risk
  • Get involved
  • Research
  • MERCK ENDO

    Acronym: 

    MERCK ENDO

    ACTRN/NCT /ethics: 

    NCT03517449

    Scientific title: 

    Lenvatinib in combination with pembrolizumab versus treatment of pysician's choice in participants with adavanced endometrial cancer (MK-3475/ E7080-G000-309 per merck standard convention [Keynote-775])

    Summary of trial and patient characteristics

    Cancer Type Gynaecological
    Trial Type Treatment
    Phase Phase III Tumour Stream Endometrial Cancer
    Age Range 18 years and older Cancer Stage Locally Recurrent or Locally Advanced
    Sex Female Anticipated Start Date 2018-06-11
    Molecular Target Anticipated End Date 2023-01-25
    Cancer Type Gynaecological
    Trial Type Treatment
    Phase Phase III
    Age Range 18 years and older
    Sex Female
    Molecular Target
    Tumour Stream Endometrial Cancer
    Cancer Stage Locally Recurrent or Locally Advanced
    Anticipated Start Date 2018-06-11
    Anticipated End Date 2023-01-25

    Trial Summary

    This is a study of pembrolizumab (MK-3475, KEYTRUDA©) in combination with lenvatinib (E7080) versus treatment of physician's choice (doxorubicin or paclitaxel) for the treatment of advanced endometrial cancer. Participants will be randomly assigned to receive either pembrolizumab and lenvatinib or treatment of physician's choice. The primary study hypothesis is that pembrolizumab in combination with lenvatinib prolongs progression free survival (PFS) and overall survival (OS) when compared to treatment of physician's choice.

    Lay Summary

    Lenvatinib in combination with pembrolizumab versus treatment of pysician's choice in participants with adavanced endometrial cancer (MK-3475/ E7080-G000-309 per merck standard convention [Keynote-775])

    Sponsor / Cooperative group

    Eisai Inc. & MERCK Sharp & Dohme Corp.

    Participating Hospitals

    Hospital Clinical Trial Coordinator Email Phone Principal Investigator Recruitment Status
    Flinders Medical Centre Alex Scott-Hoy alex.scott-hoy@sa.gov.au 08 8204 4830 Ganessan Kichenadasse Not Yet Recruiting